SCHEMBL24540955

SCHEMBL24540955

CC1(C)COCC(c2ccc(C(F)(F)F)cc2)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
SLC6A3 Q01959 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
HTR2C P28335 3/20 0.38
KDM1A O60341 2/20 0.36
RCOR1 Q9UKL0 1/20 0.36
PARP1 P09874 1/20 0.36
PARP2 Q9UGN5 1/20 0.36
BACE1 P56817 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC3 O15379 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24700187 0.83 CHRNA1 (0.44) CHRNB2CHRNB4CHRNA3CHRNA4SLC6A3
SCHEMBL25331550 0.80 TSHR (0.36) CHRNB2CHRNB4CHRNA3CHRNA4SLC6A3
SCHEMBL23123719 0.79 SLC6A2 (0.41) CHRNB2CHRNB4CHRNA3CHRNA4SLC6A3
SCHEMBL23123298 0.77 CHRNA1 (0.47) CHRNB2CHRNB4CHRNA3CHRNA4SLC6A3
SCHEMBL24700319 0.76 CHRNB2 (0.45) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL23522761 0.72 HTR2C (0.40) HTR2CKDM1ARCOR1PARP1PARP2
SCHEMBL23522762 0.72 HTR2C (0.40) HTR2CKDM1ARCOR1PARP1PARP2
SCHEMBL24540920 0.72 HTR2C (0.40) HTR2CKDM1ARCOR1PARP1PARP2
SCHEMBL23123888 0.71 KDM1A (0.46) SLC6A3KDM1ABACE1MEN1KMT2A
SCHEMBL29789673 0.71 KDM1A (0.37) CHRNB2CHRNB4CHRNA3CHRNA4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092794-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2024-03-21 US disclosed
US-11845760-B2 PRMT5 inhibitors AMGEN INC. (US) 2023-12-19 US disclosed
US-20220194955-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-23 US disclosed
US-20220194955-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-23 US disclosed
WO-2022132914-A1 PRMTS INHIBITORS AMGEN INC. (US) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092794-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 CHRM2 4075/4885CHRM4 4594/4885CHRNB2 4712/4885
US-11845760-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 CHRM2 3999/4885CHRM4 4571/4885CHRNB2 4676/4885
US-20220194955-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 CHRM2 4075/4885CHRM4 4594/4885CHRNB2 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.